Use of the Novel Plk1 Inhibitor ZK-Thiazolidinone to Elucidate Functions of Plk1 in Early and Late Stages of Mitosis

Anna Santamaria,* Rüdiger Neef,†‡ Uwe Eberspächer,§ Knut Eis,§ Manfred Husemann,§ Dominik Mumberg,§ Stefan Prechtl,§ Volker Schulze,§ Gerhard Siemeister,§ Lars Wortmann,§ Francis A. Barr,¶ and Erich A. Nigg*

*Department of Cell Biology and †Intracellular Protein Transport, Independent Junior Research Group, Max-Planck Institute of Biochemistry, Martinsried, 82152 Germany; and §Bayer Schering Pharma AG, Global Drug Discovery, Berlin, 13342 Germany

Submitted June 1, 2007; Revised July 20, 2007; Accepted July 25, 2007

Monitoring Editor: Mark Solomon

Polo-like kinase 1 (Plk1) is a key regulator of mitotic progression and cell division in eukaryotes. It is highly expressed in tumor cells and considered a potential target for cancer therapy. Here, we report the discovery and application of a novel potent small-molecule inhibitor of mammalian Plk1, ZK-Thiazolidinone (TAL). We have extensively characterized TAL in vitro and addressed TAL specificity within cells by studying Plk1 functions in sister chromatid separation, centrosome maturation, and spindle assembly. Moreover, we have used TAL for a detailed analysis of Plk1 in relation to PICH and PRC1, two prominent interaction partners implicated in spindle assembly checkpoint function and cytokinesis, respectively. Specifically, we show that Plk1, when inactivated by TAL, spreads over the arms of chromosomes, resembling the localization of its binding partner PICH, and that both proteins are mutually dependent on each other for correct localization. Finally, we show that Plk1 activity is essential for cleavage furrow formation and ingestion, leading to successful cytokinesis.

INTRODUCTION

The error-free segregation of chromosomes during cell division is necessary for the maintenance of correct ploidy and genomic integrity, and errors in cell division are presumed to lead to aneuploidy and cancer (Rajagopalan and Lengauer, 2004). To ensure that daughter cells receive the correct complement of chromosomes, two key events need to be coordinated. First, chromosomes must be equally segregated, a process that depends on the mitotic spindle. Second, cytokinesis, the process dividing the cell into two, must occur between the two sets of segregated chromosomes. Both of these processes require the activity of a key cell cycle regulator, the Polo-like kinase 1 (Plk1). Plks form a conserved subfamily of serine/threonine protein kinases. The first member to be identified was Polo in Drosophila melanogaster (Llamazares et al., 1991) and, subsequently, four Plk family members have been identified in mammals (Glover et al., 1998; Barr et al., 2004).

Plk1 contains an N-terminal kinase domain and a phosphopeptide-binding C-terminal regulatory polo-box domain (PBD; Leung et al., 2002; Elia et al., 2003b). In vertebrates Plk1 has been implicated in the activation of Cdk1-cyclin B upon entry into mitosis, centrosome maturation via the recruitment of the γ-tubulin ring complex (γ-TuRC), spindle formation, sister chromatid separation by cohesin removal from the chromosome arms, promotion of anaphase onset through direct phosphorylation of the APC/C complex as well as the inhibition of the APC/C inhibitor Emi1, and finally, mitotic exit and cytokinesis (reviewed in Barr et al., 2004). Fitting with these diverse functions, Plk1 localizes to the centrosomes, spindle poles, and kinetochores in prophase and metaphase, the central spindle in anaphase, and the midbody during cytokinesis. These localizations require the function of the PBD (Jang et al., 2002; Seong et al., 2002) and priming-kinases to generate phosphorylated docking sites that are subsequently recognized by the PBD (Elia et al., 2003b). The identification of these priming kinases is therefore important for understanding how Plk1 activity is controlled throughout mitosis as well as meiosis. In the early stages of mitosis, Cdk1 generates Plk1 docking sites (Elia et al., 2003a,b). In contrast, in anaphase Plk1 is able to self-prime its docking sites on proteins required for cytokinesis. Based on these findings, a model has been proposed to explain the temporal and spatial control of Plk1 activity (Neef et al., 2003, 2007).
Plk1 is overexpressed in a broad range of human tumors, and this is associated with poor prognosis in several types of cancer (Eckerdt et al., 2005; Takai et al., 2005). Its association with tumorigenesis indicates that Plk1 is an attractive kinase target for cancer drug development (Streberhard and Ullrich, 2006). The targeted inactivation of essential kinases is often carried out by ATP-competitive small-molecule inhibitors that block their enzymatic activity. Small-molecule inhibitors have been successfully used for the inhibition of Aurora kinases (Keen and Taylor, 2004) and Cdk5 (Fischer et al., 2003). Most recently, efforts to identify new Plk inhibitors have led to the discovery of several potent inhibitors (Mchines et al., 2006; Peters et al., 2006; Streberhard and Ullrich, 2006; Lansig et al., 2007; Lenart et al., 2007), and these new tools have been successfully used to study several aspects of Plk1 function.

Here we identify ZK-Thiazolidinone (TAL) as a novel ATP-competitive inhibitor of Plk1. Following an extensive characterization of this new inhibitor in vitro, we have addressed its specificity within intact cells by systematically analyzing its ability to counteract the role of Plk1 in previously established functions, notably sister chromatid separation, centrosome maturation, and bipolar spindle assembly. Our results confirm the requirement of Plk1 kinase activity for all these functions, indicating that TAL acts as a specific and potent Plk1 inhibitor in vivo. Having established TAL specificity, we have then used this novel inhibitor to gain further insights into the targeting and regulation of Plk1 at different times throughout mitosis and cytokinesis. Specifically, we have explored the relationship between the catalytic activity of Plk1 and the recently identified Plk1-interacting checkpoint helicase PICH (Baumman et al., 2007), and we have used TAL as a potent tool for studying Plk1 function at the central spindle during cytokinesis. Our results provide strong support for the recently proposed self-priming model of Plk1 targeting in anaphase cells (Neef et al., 2007) and help to explain the temporal regulation of Plk1 during mitotic exit and cytokinesis.

MATERIALS AND METHODS
Preparation of TAL Inhibitor
TAL was prepared as described (Schulze et al., 2006). In vitro and in vivo experiments TAL was used from a stock solution (10 mM) in dimethyl sulfoxide (DMSO).

In Vitro Kinase Assays
Recombinant baculoviruses expressing full-length His-tagged Plk1 were produced using the BaculoGold kit according to manufacturer’s instructions (BD Biosciences Pharmingen, San Diego, CA). Glutathione S-transferase (GST)-tagged Plk1 wild type (WT; residues 1–265) and kinase dead (KD; D14A) and His-tagged Aurora A (Kufer et al., 2002) were purified from E. coli. GST-tagged Aurora B (Neef et al., 2006) was purified from 293 cells. Cdk1 was obtained commercially (Upstate Biotechnology, Lake Placid, NY). In vitro phosphorylation reactions on different model substrates were carried out in BRBB80 buffer (Stucke et al., 2004) in the case of Plk1, Plk4, and Cdk1 or a follow-up described protocol for Aurora A (Kufer et al., 2002). Reactions were supplemented with 10 μM ATP and 2 μCi γ-32P-ATP (Amersham Pharmacia Biosciences, Piscataway, NJ). In vitro phosphorylation using Mkp2 was performed using 200 ng of substrate, 10 μM ATP and 2 μCi γ-32P-ATP, in a total volume of 20 μl BRBB80 for 30 min at 30°C. Reactions were stopped by the addition of SDS sample buffer and heating to 95°C. Reactions products were visualized by SDS-PAGE followed by autoradiography.

To determine the half-maximal growth inhibition (IC50) of Plk1, activity assay was performed for 90 min at 22°C in presence of serial dilutions of inhibitor in a total volume of 31 μl using cells from bovine milk (Sigma, St. Louis, MO) as the substrate (0.06 μg/ml Plk1, 0.7 μM biotinylated casein, 50 μM HEPES, pH 7.5, 10 mM MgCl2, 3 mM MnCl2, 1 mM dithiothreitol, 0.01% Nonidet P40, 0.5% DMSO, 0.5 μM ATP, and 50 nCi γ-32P-ATP). Reactions were terminated by addition of 50 μl of SPA suspension (100 μM ATP, 10 μM EDTA, 0.2% Triton X-100, 2.5 mg/ml streptavidin-coated SPA beads [Amer- sham Pharmacia Biosciences] in phosphate-buffered saline). SPA beads were allowed to sediment over night at 22°C, and incorporated 32P was determined using a TopCount scintillation counter (Perkin Elmer-Cetus, Norwalk, CT). Dose–response curves were used to calculate IC50 values. The same procedure was followed to test a panel of 93 serine/threonine kinases.

Cell Culture and Synchronization
Human MCF7, NCI-H460, DU145, HeLa S3, mouse B16-F10, and Caco-2 cells were obtained from the American Type Culture Collection (Manassas, VA). Cells were grown at 37°C under 5% CO2, either in DMEM (HeLa S3) or in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum and penicillin and streptomycin (100 U/ml and 100 mg/ml, respectively). Thymidine arrest was performed for 14 h at a concentration of 4 mM. Nocodazole and taxol arrests were performed for 16 h at concentrations of 0.2 μg/ml and 1 μg/ml, respectively. Cells arrested in metaphase were obtained by treating cells with 25 μM nocancipine or 20 μM VS-83 for 10 h and subsequently 2 h with 20 μM MG1132.

In Vitro Cell Proliferation Assays
Cells were seeded in 96-well plates at 1500 (Caco-2), 3000 (H460, HeLa), or 5000 (MCF7, DU145) cells/well. Cells were allowed to adhere for 24 h and then fresh growth medium plus serial dilutions of inhibitor compounds were added. The final concentration of the solvent DMSO was 0.5%. After 4 d of continuous incubation, the cells were fixed with glutaraldehyde and stained with crystal violet, and the absorbance was recorded at 595 nm. All measurements were done in quadruplicates. The values were normalized to the absorbance of solvent-treated cells (= 100%), and the absorbance of a reference plate, which was fixed at the time point of compound application (= 0%). IC50 was determined as compound concentration that was required to achieve 50% inhibition of cellular growth.

Fluorescence-activated Cell Sorting Analysis
HeLaS3 (Figure 1C) or HeLaS3 and MCF-7 cells (Supplementary Figure 2) were incubated with 0.5% DMSO or 1 μM TAL at different time points (Figure 1C) or various concentrations of TAL for 24 h (Supplementary Figure 2). Cell suspensions were fixed with 80% ethanol, permeabilized by treatment for 5 min with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/ml propidium iodide. Cellular DNA content was determined by flow cytometry using FACSCaliber (BD Biosciences Clontech, San Jose, CA) system and CellQuest software (Becton-Dickinson, Lincoln Park, NJ).

Transient Transfection and Small Interfering RNA
Plasmid transfections were performed using FuGENE 6 reagent (Roche Diagnostics, Indianapolis, IN) according to manufacturer’s instructions. Small interfering RNA (siRNA) duplexes were transfected using Oligoportamine (Invitrogen). In siRNA experiments, BubR1 siRNA duplexes (5′-GGAGATCCTTCTACAAAGG) were purchased from Qiagen (Hilden, Germany). Plk1, Mad2, BubR1, Eg5, and PICH (oligo 1) were depleted using previously published duplexes (Stucke et al., 2004; Baumecke et al., 2004; Hanisch et al., 2006; Baumecke et al., 2007), and the GL2 duplex (Elbashir et al., 2001) was used for control. For rescue experiments, the Plk1-siRNA plasmid was transfected simultaneously with myc-Plk1 WT or KD constructs, following established protocols (Hanisch et al., 2006).

Mitotic Chromosome Spreads
HeLa S3 cells were either treated with VS-83 or TAL overnight. Mitotic cells were collected by shake-off. Chromosome spreads were obtained following established protocols (Hanisch et al., 2006).

RESULTS
TAL Specifically Inhibits Plk1 Activity
Screening of the Schering compound collection for inhibition of Plk1 kinase activity resulted in the identification of the Thiazolidinone lead series. The Thiazolidinones represent a novel chemical class of kinase inhibitors. They do not contain either of three preferred structural motifs of ATP-competitive kinase inhibitors (Perola, 2006) and, in particular, they are distinct from previously described Plk1 kinase inhibitors (Andrews et al., 2004; Davis-Ward et al., 2004; Bearss et al., 2006; Perola, 2006; Steegmaier et al., 2007). The compound characterized here, ZK-Thiazolidinone (Figure 1A) is hereafter referred to as TAL. As assayed under specific in vitro conditions TAL inhibited human Plk1 with an IC50 of 19 ± 12 nM (Supplementary Figure 1B; for assay conditions see Materials and Methods). When tested against a panel of 93 serine/threonine and tyrosine kinases, the compound
showed high selectivity for Plk1 (Supplementary Table 1 and Supplementary Figure 1A). The only other kinases showing significant sensitivity to TAL were the two closest relatives of Plk1: Plk2 and Plk3, which were inhibited at IC_{50} of lower than 100 nM (data not shown). In contrast, no significant inhibition could be seen for Plk4 (Supplementary Figure 1A). We also tested the ability of TAL to inhibit Plk1 activity using the physiological Plk1 target Mklp2 as a substrate (Neef et al., 2003) and found strong inhibition of Mklp2 phosphorylation by 250 nM TAL (Figure 1B). Taking together, these results show that TAL potently and selectively inhibits Plk1 in vitro.

**TAL Treatment Results in an Increased Mitotic Index Due to Checkpoint Activation**

Consistent with Plk1 inhibition, TAL inhibited the proliferation of various human and mouse tumor cell lines with an IC_{50} of 0.2–1.3 μM (Supplementary Figure 1C). Because Plk1 activity is essential for mitotic progression, we analyzed the effect of TAL on the cell cycle of HeLa S3 and MCF7 cells by flow cytometry. Within 24 h of treatment with increasing concentrations of the compound, TAL induced an accumulation of HeLa S3 and MCF7 cells with a 4N DNA content, indicative of a G2/M arrest (Supplementary Figure 2). Concomitantly, a striking increase in the mitotic index (Supplementary Figure 1D) and an increase in phospho-histone H3 staining (Supplementary Figure 1E) could be observed. At concentrations above 10 μM, increasing cell death was observed, dependent on cell line and duration of exposure (data not shown), in agreement with the reported effect of Plk1 depletion in tumor cells (Liu and Erikson, 2003; Liu et al., 2006). We also tested the reversibility of 1 μM TAL treatment of HeLa S3 cells. After 12 h of treatment, a release for 12 h into fresh medium readily reversed the G2/M block (Figure 1C). A mitotic arrest was maintained during a 24 h treatment, but after 48 h an elevated proportion of cells with sub-2N DNA content was observed, indicative of cell death (Figure 1C). Because of the clear accumulation of mitotic cells in response to 12 h treatment with 1 μM TAL (Figure 1C), the absence of cell death and the reversibility of the block, we used 1 μM for 12 h as a standard condition for most of the following experiments.

The predominant phenotype seen upon depletion of Plk1 is a cell cycle arrest in prometaphase (Sumara et al., 2004; Van Vugt et al., 2004). In line with these observations, treatment of asynchronously growing HeLa S3 cells with 1 μM
TAL resulted in a prometaphase-like arrest characterized by frequent monopolar spindles and kinetochores that were positive for Mad2 (Figure 1D), indicating that kinetochores were either not attached to the spindle or not fully occupied by microtubules. Depletion of either BubR1 or Mad2, two key regulators of the spindle assembly checkpoint (SAC), suppressed the mitotic arrest caused by TAL treatment (Figure 1E), demonstrating its checkpoint dependence. Live cell microscopy also confirmed that TAL-treated cells failed to form a normal metaphase plate and instead arrested with monopolar spindles, whereas control cells entered anaphase 30 min after nuclear envelope breakdown (Figure 1F and Supplementary Movies S1 and S2).

TAL Treatment Produces Mitotic Defects Expected for Plk1 Inhibition

To further validate the specificity of TAL for Plk1 within living cells, we examined the ability of this compound to interfere with selected processes that are known to require Plk1 activity, notably centrosome maturation, sister chromatid cohesion, and spindle formation. These processes have previously been studied extensively, and they all concern early stages of mitosis (Barr et al., 2004). Most recently, they have also been used to validate the specificity of other, structurally distinct Plk1 inhibitors (McInnes et al., 2006; Peters et al., 2006; Lansing et al., 2007; Lenart et al., 2007).

The first process we examined is centrosome maturation at the G2/M transition. At this stage of the cell cycle, additional γ-TuRCs are recruited to the centrosome to enhance microtubule nucleation at the onset of mitosis (Khodjakov and Rieder, 1999; Palazzo et al., 2000). A role for Plk1 in centrosome maturation was originally established through antibody injection (Lane and Nigg, 1996) and more recently confirmed by siRNA-mediated Plk1 depletion (Sumara et al., 2004; Hanisch et al., 2006). After treatment of cells with TAL, γ-tubulin recruitment to centrosomes (identified by pericentrin staining) was clearly impaired (Figure 2A), very similar to the phenotype seen after depletion of Plk1 (Sumara et al., 2004; Hanisch et al., 2006). For control, untreated cells or cells displaying a similar cell cycle arrest phenotype due to inhibition of the kinesin-related motor Eg5 (Blangy et al., 1995) were analyzed in parallel and found to show normal γ-tubulin recruitment (Supplementary Figure 3 and Figure 2A). Interestingly, in TAL-treated cells, Plk1 itself failed to localize to centrosomes (see Figure 5 and Supplementary Figure 4), in agreement with a recent study using the Plk1 inhibitor BI 2536 (Lenart et al., 2007). In human cells, Plk1 depletion also impairs the recruitment of Aurora A kinase to the centrosome (De Luca et al., 2006; Hanisch et al., 2006), which might provide a plausible explanation for the Aurora A requirement in centrosome maturation observed in invertebrates (Hannak et al., 2001; Berdnik and Knoblich, 2002). The availability of TAL afforded a unique opportunity to address the question of whether Plk1 activity is required for Aurora A recruitment. As shown in Figure 2B, Aurora A failed to localize to centrosomes in TAL-treated cells, similar to the phenotype seen in Plk1-depleted cells, but not in untreated cells or Eg5-depleted cells, analyzed for control (Supplementary Figure 3 and Figure 2B). Instead, in both TAL-treated cells and Plk1-depleted cells, Aurora A associated predominantly with spindle microtubules (Figure 2B). Eg5 localization was not affected upon TAL treatment (Figure 2C) nor...
were the levels of Plk1, Eg5, γ-tubulin, and Aurora A proteins (Figure 2D). These results not only confirm that Plk1 acts upstream of Aurora A (De Luca et al., 2006; Hanisch et al., 2006), but further demonstrate that Plk1 activity is required for Aurora A recruitment to centrosomes.

Most recently, evidence has emerged for additional roles of Plk1 in spindle formation and maintenance (Sumara et al., 2004; Peters et al., 2006) as well as in kinetochore-microtubule attachment and chromosome congression (Hanisch et al., 2006; Lenart et al., 2007). To determine whether Plk1 activity is required for the maintenance of spindle bipolarity, HeLa S3 cells synchronized to display bipolar spindles (see Materials and Methods) were treated with TAL and followed by live cell videomicroscopy over time (Supplementary Movie S3 and Figure 3A). In parallel, cells were fixed and stained with anti-α-tubulin antibodies (Figure 3B). Although control cells (treated with DMSO solvent only) readily maintained bipolar spindles and chromosomes in a metaphase I state (Figure 3A and data not shown), in TAL-treated cells bipolar spindles progressively collapsed to yield monopolar microtubule arrays (Figure 3, B and C), and metaphase plates became disorganized (Figure 3, A and B). Most likely, this phenotype results from a shortening of kinetochore fibers (K-fibers) for the benefit of microtubule bundles that extend from the spindle pole to the cell periphery (Figure 3B, 60 and 120 min, arrows). These results confirm and extend those recently reported by Kapoor and colleagues (Peters et al., 2006) using a chemically distinct Plk1 inhibitor.

To explore the suspected role of Plk1 in K-fiber stabilization, K-fibers were stained with anti-HURP antibodies (Sillje et al., 2006) before and after cold treatment (Rieder and Borisy, 1981). For comparison, monoastral spindles were produced in control cells by treatment with VS-83, a small-molecule inhibitor of Eg5 (Sarli et al., 2005). Although HURP-positive K-fibers could readily be seen in both VS-83 and TAL-treated cells at time zero (Figure 4A, left), cold treatment for 20 min virtually abolished HURP staining in TAL-treated cells but not in VS-83 treated cells (Figure 4A, right). Furthermore, unlike the situation in VS-83 cells, the thin and long microtubules observed in TAL-treated cells did not end at kinetochores, as shown by costaining with CREST kinetochore serum (Figure 4A, bottom panels). These data lend strong support to the view that Plk1 activity is required to maintain stable kinetochore-microtubule interactions.

As a final validation of TAL specificity, we examined a third well-established function of vertebrate Plk1, namely the removal of cohesins from the arms of sister chromatids during prophase (Losada et al., 2002; Sumara et al., 2002; Losada, 2007). As shown by the analysis of chromosomes spreads, sister chromatid arms remained paired in cells treated with TAL, whereas the expected X-shaped chromosomes, indicative of arm separation, were seen in control cells treated with VS-83 (Figure 4B). Collectively, our analysis of the effect of TAL on centrosome maturation, bipolar spindle formation, and sister chromatid cohesion demonstrate that this Plk1 inhibitor produces phenotypes that are entirely consistent with our current understanding of Plk1 function, lending strong support for its in vivo specificity.

Having established confidence in the reliability of TAL as a new research tool to study Plk1 function, we next proceeded to use TAL for a more detailed analysis of Plk1 in relation to two recently identified interaction partners, notably PICH implicated in SAC function (Baumann et al., 2007) and PCR1, a putative protein scaffold playing a key role in cytokinesis (Neet et al., 2007).

**Spreading of Plk1 and PICH over Chromatid Arms upon Plk1 Inactivation**

Having identified PICH as a prominent Plk1-interaction partner and substrate in prometaphase, we took advantage of TAL to explore the consequences of Plk1 inhibition on the localization of PICH and Plk1 (Figure 5). To provide controls with monoastral spindles, Eg5-depleted cells were analyzed in parallel. On inhibition of Plk1 by TAL, PICH was found to spread over chromatid arms, similar to the phenotype seen...
in Plk1-depleted cells (Figure 5A). This confirms that Plk1 is required to remove PICH from chromatid arms (Baumman et al., 2007) and further demonstrates a requirement for Plk1 activity. Interestingly, when compared with (Eg5 depleted) control cells, Plk1 itself was also found to spread over chromatid arms in response to TAL treatment (Figure 5B), suggesting that Plk1 activity is required to concentrate this kinase at the kinetochore. To mimic the situation seen in TAL-treated cells, we overexpressed myc-tagged kinase dead (Plk1 KD) in Plk1-depleted cells. Cells moderately overexpressing myc-tagged Plk1 KD showed staining of chromatid arms very similar to that seen for endogenous Plk1 in TAL-treated cells, whereas Plk WT analyzed for control remained concentrated at kinetochores (Supplementary Figure 4B). These results indicate that Plk1 interacts with a docking partner on chromatid arms, whose localization is sensitive to Plk1 activity.

Because the chromosomal localization of PICH is clearly controlled by Plk1 (Figure 5A and Baumman et al., 2007), we considered this protein a likely candidate for the recruitment of Plk1 over chromatid arms. To test this hypothesis, we first used TAL to confirm that the electrophoretic mobility shift seen in PICH during mitotic arrest is due to Plk1 activity (Figure 5B), suggesting that Plk1 activity is required to concentrate this kinase at the kinetochore. To mimic the situation seen in TAL-treated cells, we overexpressed myc-tagged kinase dead (Plk1 KD) in Plk1-depleted cells. Cells moderately overexpressing myc-tagged Plk1 KD showed staining of chromatid arms very similar to that seen for endogenous Plk1 in TAL-treated cells, whereas Plk WT analyzed for control remained concentrated at kinetochores (Supplementary Figure 4B). These results indicate that Plk1 interacts with a docking partner on chromatid arms, whose localization is sensitive to Plk1 activity.

Inhibition of Plk1 Activity by TAL Leads to Cytokinesis Failure

In the past, it has been difficult to pinpoint a specific role for Plk1 in postanaphase events, because of multiple requirements for this kinase at earlier stages of mitosis. Thus, in the final series of experiments, we used TAL to explore the purported role of Plk1 in cytokinesis (Mundt et al., 1997; Carmena et al., 1998; Nigg, 1998; van Vugt and Medema, 2005). TAL treatment of cells released from an MG132 induced metaphase phase arrest caused extensive multinucleation, confirming the requirement for Plk1 for cell division (Supplementary Figure 5, A and B). To examine this phenotype in more detail, we performed live cell imaging on asynchronous cultures of HeLa S3 cells treated with TAL. In cells that were in prophase or prometaphase at the time of TAL addition, bipolar spindle collapsed into a monopole (Figure 6A), arguing that TAL exerts its Plk1-inhibitory effect rapidly after addition. Of the cells showing already aligned chromosomes when the drug was added, spindle bipolarity was similarly lost in 30% of cells, whereas 70% progressed into anaphase and segregated their chromosomes normally but then failed to complete cytokinesis, resulting in binucleation (Figure 6A). This argues that events early in anaphase are regulated by Plk1 and crucial to ensure proper cytokinesis. Finally, cells that were already in telophase or cytokinesis at the time of TAL addition completed normal division (Figure 6A). Careful examination of cells that had aligned chromosomes at the time of TAL addition...
Figure 5. Plk1 and PICH spread over chromatid arms upon TAL addition. (A and B) HeLa S3 cells were transfected with Eg5 or Plk1 siRNA-oligos for 36 h or treated with 1 μM TAL for 12 h. Cells were fixed and stained for PICH and Plk1 (A and B, respectively; green), CREST (red), and DNA (blue). Scale bar, 10 μm. (C) Lysates from nocodazole (0.2 μg/mL) or taxol (1 μg/ml) arrested cells, treated with DMSO or 1 μM TAL were used for Western blot analysis. Membranes were probed for PICH, phospho-H3, cyclin-B, and α-tubulin as loading control. (D) HeLaS3 cells were treated under different conditions: first column, DMSO for 12 h; second column, TAL for 12 h; third column, PICH-siRNA oligo for 36 h; and fourth column, PICH-siRNA oligo for 36 h together with TAL during the last 12 h. Cells were fixed and stained for PICH (red) and Plk1 (green), and DNA was stained with DAPI (blue). Scale bar, 10 μm.
Figure 6. Plk1 activity is required for successful cytokinesis. (A) Quantification of the percentage of cells in different stages of mitosis that upon TAL treatment collapsed into monopolar spindles or went through mitosis completing normal division or failing in cytokinesis. Approximately 100 cells were counted in two independent experiments performed by live-cell imaging. (B) The failure in cytokinesis with or without furrow ingression was analyzed and plotted for the cells in metaphase or anaphase from the previous experiment. (C) Representative stills from these movies are shown. Time = 0 represents the stage in mitosis at the time of addition of the inhibitor. Top panels, a control cell that progress normally through mitosis (DMSO); bottom panels, cells that fail in cytokinesis with or without furrow formation and ingression (TAL panels, upper two rows and lower two rows, respectively).
revealed that most of these cells (>70%; Figure 6B) failed to display cleavage furrow ingression, again indicating an early requirement for Plk1 activity in this process (Figure 6C, bottom, upper two rows, and Supplementary Movie S4). In contrast, cells already in anaphase at the time of TAL addition mostly showed transient furrow ingression (>90%; Figure 6B), and yet cytokinesis ultimately failed (Figure 6C, bottom, lower two rows, and Supplementary Movie S5).

The furrowing defects in Plk1-inhibited cells suggested that some aspects of cleavage furrow formation were impaired. We therefore looked at the localization of the RhoA GTPase, the essential regulator of actomyosin dynamics during cytokinesis, and its upstream guanine nucleotide exchange factor (GEF) ECT2 to the equatorial cell cortex and central spindle, respectively. Strikingly, TAL suppressed RhoA recruitment to the equatorial cell cortex, implying that Plk1 acts upstream of RhoA (Figure 7A). We then investigated the effects of TAL on ECT2, because the localized activation of RhoA at the cleavage furrow is dependent on this GEF (Yuce et al., 2005). This showed that ECT2 was lost from the central spindle in TAL-treated cells (Figure 7B), explaining why RhoA is lost from the equatorial cell cortex and cleavage furrow ingression fails upon Plk1 inhibition.

Figure 7. Plk1 activity is required for proper furrow ingression. (A and B) Control HeLa cells (left, DMSO) and cells treated for 30 min with 1 μM TAL (right) were fixed and stained for RhoA or ECT2 (A and B, respectively; green), actin (B; red), and DNA (blue). Cells in early and late anaphase stages are shown in the control.

Plk1 targeting during anaphase has been suggested to control its localization during anaphase and cytokinesis through a self-priming feedback mechanism (Neef et al., 2003, 2007). To further test this hypothesis, we investigated two Plk1 docking partners at the central spindle required for cytokinesis, notably the kinesin-6 family motor Mklp2 and the central spindle microtubule-associated protein PRC1. Control cells treated with DMSO showed normal staining for Plk1, Mklp2, and PRC1 (Figure 8A, left). In contrast, after Plk1 inhibition with TAL the central spindle was highly disorganized and Plk1 staining was lost during anaphase and telophase (Supplementary Figure 5C; Figure 8A, right). This suggests that Plk1 must generate a docking site on its major central spindle-binding partners. Phosphorylation of Mklp2 by Plk1 is necessary for Mklp2 function and Plk1 localization to the central spindle in late anaphase and telophase (Neef et al., 2003), but so far the consequences of this phosphorylation for the Mklp2 localization could not be addressed. After TAL treatment the central spindle localization of Mklp2 was strongly reduced and a more cortical staining appeared (Figure 8A, right). Because Mklp2 is required for the relocation of Aurora B from the kinetochores to the central spindle (Gruneberg et al., 2006), we asked whether the localization of Aurora B was altered in TAL-treated cells. As shown in Supplementary Figure 5C, Aurora B also showed a cortical localization after inhibitor treatment, most likely representing the pool of Aurora B...
bound to the displaced Mklp2, whereas the central spindle localization of Aurora B was diminished. PRC1 localization at the central spindle is also affected in Mklp2-depleted cells (Neef et al., 2007). Therefore, we analyzed PRC1 localization after treatment with TAL. After inhibition of Plk1 activity, PRC1 localized to the disorganized central spindle in early anaphase (Figure 8A). However, in late anaphase/telophase, PRC1 failed to form a focused band and spread out along the entire length of the microtubule bundle (Figure 8A, right), resembling the localization in Mklp2-depleted cells (Neef et al., 2007). In addition, very strong microtubule bundles were observed, resembling the phenotype generated upon depletion of endogenous PRC1 and concomitant rescue with a docking site mutant of PRC1 (S602A mutant), which is unable to bind and localize Plk1 (Neef et al., 2007). Phosphospecific antibodies to this site (pT602) specifically stained the central spindle in control cells, and this staining was lost upon Plk1 inhibition (Figure 8A, right), confirming the specific phosphorylation by Plk1 on this site. In contrast, staining for Mklp1 and for phospho-S911 Mklp1, an Aurora B phosphosite (Neef et al., 2006), were comparable with or without TAL treatment (Figure 8A).

Finally, we used the TAL inhibitor to confirm that the PRC1-T602 phosphorylation by Plk1 correlates with Plk1 binding in vivo. As shown previously, Plk1 and PRC1 did not interact in metaphase (Figure 8B, 0 min nocodazole release), when PRC1 is phosphorylated at T481 by Cdk1 (Neef et al., 2007). After 80-min release from nocodazole, cells entered anaphase, as shown by the dephosphorylation of PRC1 at T481 and the phosphorylation at PRC1 T602 by Plk1. In these anaphase cells, Plk1 precipitated with PRC1. However, when the release was performed in the presence of TAL, T602 was not phosphorylated and the amount of Plk1 precipitated together with PRC1 was significantly re-
duced. Together with the previously reported data this shows that active Plk1 is required for the generation of its own binding site on PRC1 in anaphase. Thus, the use of TAL in the above experiments provides strong support for the previously proposed self-priming model (Neef et al., 2003, 2007).

**DISCUSSION**

**Specific Inhibition of Plk1 by TAL In Vitro and In Vivo**

Here we have characterized TAL, a new potent and specific inhibitor of Plk1. Importantly, TAL is built on a novel chemical scaffold and structurally distinct from other Plk1 inhibitors recently described (McInnes et al., 2006; Peters et al., 2006; Lansing et al., 2007; Lenart et al., 2007). Because specificity is a general concern when using small molecule inhibitors to study biological processes, results can be viewed with increased confidence whenever chemically distinct compounds produce consistent phenotypes. Using TAL, we have been able to confirm functions previously attributed to Plk1, attesting to the selectivity of this compound. In addition, the use of TAL has allowed us to enhance our understanding of Plk1 function in mitotic spindle formation, chromosome arm separation, and the temporal and spatial control of Plk1 during mitosis and cytokinesis. These findings are discussed in more detail in the following sections.

**Plk1 Activity in Mitotic Spindle Formation and Chromosome Congression**

Bipolar spindle formation and maintenance involves the remodeling of the microtubule nucleating and organizing capacities of the spindle poles, as well as proper kinetochore-microtubule attachment. Plk1 is involved in both processes and may be important to help coordinate these events. It has previously been shown that Plk1 is needed to recruit γ-tubulin to the centrosomes in order to enhance microtubule nucleation activity in preparation of bipolar spindle formation (Khodjakov and Rieder, 1999; Palazzo et al., 2000). Our present study not only confirms that this function depends on Plk1 activity, but also demonstrates that Plk1 activity is needed for Aurora A localization to the centrosomes. This is significant because Aurora A, together with its partner TPX2, is known to be required for normal spindle formation (Kufer et al., 2002; Tsai et al., 2003; Eyer and Maller, 2004). Once mitotic spindles have formed, Plk1 is also required for the maintenance of spindle bipolarity, as shown by the use of two chemically distinct Plk1 inhibitors (Peters et al., 2006 and our present study). This intriguing observation suggests that Plk1 substrates involved initially in spindle formation must remain phosphorylated and/or that additional substrates need to be phosphorylated in order to maintain the bipolarity of already formed spindles. With regard to chromosome congression, our present data strengthen the emerging view that Plk1 contributes to stabilize kinetochore-microtubule attachments. This may reflect a role for Plk1 in the generation of spindle forces that stabilize kinetochore-microtubule attachments (Sumara et al., 2004; Hanisch et al., 2006; Lenart et al., 2007), potentially through direct phosphorylation of Plk1 substrates at the kinetochore. With the aid of Plk1 inhibitors such as TAL it should be possible to further address these issues.

**Mutual Dependency of Plk1 and PICH in Chromosome Localization**

Two mitotic kinases, Polo-like kinase and Aurora B, have been implicated in cohesin release during mitotic prophase (Losada et al., 2002; Sumara et al., 2002). Plk1 can directly phosphorylate cohesin subunits, but a direct interaction between Plk1 and cohesin has not been reported and it is not known how phosphorylation leads to the dissociation of cohesin from chromosomes. Also, other factors such as Wapl are clearly involved in regulating cohesin dissociation (Gandhi et al., 2006; Kueng et al., 2006). Here, we show that Plk1 spread over chromatid arms when its activity is inhibited with TAL. A similar redistribution after Plk1 depletion was previously observed for PICH, one of the binding partners of Plk1 during mitosis (Baumman et al., 2007). Our results with the TAL inhibitor directly link the localization of PICH over chromatid arms to Plk1 activity. Moreover, our data clearly demonstrate interdependency between these two proteins in that Plk1 remains at kinetochores upon TAL treatment of PICH-depleted cells. Under normal circumstances, we envision that Plk1 gets recruited to PICH (through a Cdk1-dependent priming event) and that a PICH-Plk1 complex has the ability to spread over chromatid arms. Our present results clearly indicate that PICH is a major interaction partner of Plk1 on chromatid arms and it will be interesting to explore whether this complex is mechanistically related to the removal of cohesins by Plk1. In any case, in response to phosphorylation by Plk1, PICH is released from chromatid arms, resulting in its concentration at the centromere/kinetochores (Baumman et al., 2007).

**Temporal Regulation of Plk1 Localization and Activity**

Plk1 regulates different processes in a spatially and temporally controlled manner through its specific recruitment to different substrates and subcellular structures that have been phosphorylated by appropriate priming kinases (Elia et al., 2003a). The prevailing evidence indicates that Cdk1 is a major priming kinase, albeit not the only one, able to create Plk1 docking sites (Raub et al., 2005; Yamaguchi et al., 2005; Oshimori et al., 2006; Qi et al., 2006; Baumman et al., 2007), but there is also evidence that Plk1 is itself able to generate docking sites, particularly during late stages of mitotic progression when Cdk1 levels have fallen (Neef et al., 2003, 2007). In a recent study, Plk1 levels at both kinetochores and centrosomes were reported to be strongly reduced in response to inhibition of Plk1 activity (Lenart et al., 2007), and Plk1 has been reported to create a docking site on the kinetochore protein PBIP-1 (Kang et al., 2006). However, after exposure of cells to TAL we did not observe a strong reduction in Plk1 levels at kinetochores, although this was difficult to quantify in view of the spreading of Plk1 over chromatid arms (see above). In agreement with Peters and coworkers (Lenart et al., 2007), we also found that the centrosome localization of Plk1 during early mitosis was sensitive to Plk1 inhibition by TAL. Potential interaction partners of Plk1 at the centrosome have previously been identified (Casenghi et al., 2003; Oshimori et al., 2006), and it will be interesting to explore through what mechanism(s) Plk1 activity is required for centrosomal localization of this kinase.

**Plk1 Function in Cytokinesis**

Before the availability of small-molecule inhibitors, defining the precise roles of Plk1 in cytokinesis was difficult because of the early prometaphase arrest produced by Plk1 depletion. Using the advantage of chemical inhibitors to block Plk1 activity in a temporally controlled manner, we show that the addition of TAL to asynchronously growing cell populations produces widely different phenotypes, depending on the exact time of addition. In particular, when cells
were already about to enter anaphase at the time of TAL addition, the inhibition of Plk1 abolished both cleavage furrow formation and ingress. In contrast, when cells had already progressed to late anaphase at the time of TAL addition, furrow formation and partial ingress could be observed, before furrows regressed and cells failed to undergo cytokinesis. Collectively, these data demonstrate that the exact cell cycle position is critical for the phenotypic consequences of Plk1 inhibition.

During anaphase, antiparallel microtubules are bundled by kinesin motors and microtubule-associated proteins, mainly PRC1 (reviewed in Glotzer, 2005). Here, we have shown that TAL treatment causes the disorganization of the central spindle and concomitant Plk1 displacement, suggesting that this phenotype may result from the lack of phosphorylation on the prominent Plk1-docking partners PRC1 and Mklp2, both of which have previously been shown to be required for Plk1 recruitment to the central spindle. We further show that Plk1 is a critical upstream activator of the ECT2-RhoA cascade that is required to initiate cytokinesis. This conclusion has been confirmed independently with other small-molecule inhibitors (Brennan et al., 2007; Petronczki et al., 2007) and also through a chemical genetics approach using an allele-specific Plk1 inhibitor (Burkard et al., 2007). Because ECT2 can activate RhoA globally, additional mechanisms are required to restrict the equatorial localization of RhoA. Here, we show that TAL treatment inhibits both the localization of ECT2 at the central spindle and the recruitment of RhoA to the equatorial cell cortex in anaphase. Conceivably, Plk1 may control the localization and activation of RhoA by directly affecting RhoA itself or its upstream regulators, such as CYK-4 and ECT2. Clearly, TAL represents a useful tool to further explore the role of Plk1 in cytokinesis and to search for the direct substrates that are relevant to this process.

The Future of Plk1 Inhibitors

Clearly, Plk1 inhibitors such as the compound TAL described here represent powerful research tools. They hold great promise for the identification and characterization of new Plk1 substrates at the centrosomes, kinetochores, and central spindle, and this in turn will help to better understand the spatial and temporal regulation of mitotic progression and cell division. Whether Plk1 inhibitors will also prove valuable in a therapeutic context remains to be seen. Recently, the crystal structure of a Plk1 kinase domain mutant (T210V) in a complex with the nonhydrolyzable ATP analogue adenylylimidodiphosphate (AMPPNP) has been reported (Kothe et al., 2007). This and additional structural information, notably of the kinase domain in either the active or inhibitor-bound state, will be very helpful for the optimization of inhibitors, such as to achieve anti-proliferative effects in tumor cells at submicromolar drug concentrations. Another crucial step toward clinical success will be to understand how the mitotic arrest caused by the inhibition of Plk1 is linked to the induction of cell death. Finally, it will be attractive to monitor potential synergistic effect of Plk1 inhibitors with other compounds that target, for example, the mitotic spindle apparatus.

ACKNOWLEDGMENTS

We thank the project team at Bayer Schering Pharma for their contribution and Anja Wehen for technical assistance. We are grateful to the “check-point-lab” for insightful discussions, Jorge Martinhalbo for initial advice, Sabine Elowe for critical reading of the manuscript, and Thomas Gaitanos for help with data analysis. We also thank Vasiliki Sarli (University of Leipzig, Institute for Organic Chemistry, Leipzig, Germany), Athanasios Giannis (University of Leipzig, Institute for Organic Chemistry, Leipzig, Germany), Stefan Hümmer (Max-Planck Institute for Biochemistry, Chemical Genetics, Independent Research Group, Martinsried, Germany), and Thomas Mayer (Max-Planck Institute for Biochemistry, Chemical Genetics, Independent Research Group, Martinsried, Germany) for providing VS-83 compound. Robert Habedank (Max-Planck Institute for Biochemistry, Department of Cell Biology, Martinsried, Germany) for providing Plk4 kinase, Jens Westendorf for help with the flow cytometer, and all members of the Nigg department for kindly sharing reagents and discussion. This work was supported by the Max-Planck Society.

REFERENCES


